US-based clinical-stage bio-technology company Rigel Pharmaceuticals has announced the pricing for its underwritten public offering of 20 million shares to be $2 a share.
The offering will raise net proceeds of approximately $37.4m, which is intended to be used for research and development (R&D), commercial preparation, and general corporate purposes. The remaining amount will be utilised to either acquire or invest in businesses and to invest in interest-bearing instruments of investment-grade.
Canadian pharmaceutical company VANC Pharmaceuticals has announced that it intends to raise C$1.3m ($0.99m) in gross proceeds from private placement of up to 5.4 million units comprising one common share and one transferrable share purchase warrant, at a price of C$0.24 ($0.18) a unit.
The proceeds are intended to be used for general corporate and working capital purposes.
US-based oncology and dermatology bio-pharmaceutical company Provectus Biopharmaceuticals has announced that it will raise $19.66m in gross proceeds through a rights offering of 19.6 million units priced at $1 a unit.
Each unit comprises up to 7.8 million shares of its common stock and up to 9.8 million shares of series C convertible preferred stock.
Part of the proceeds will be used for the clinical development of its pipeline drugs targeting locally advanced cutaneous melanoma, metastatic melanoma, cancers of the liver and other solid tumours, while the remaining will be used for general corporate purposes.